@article{MAKHILLJAVA200871124,
    title = {Antibody Development in Swine Against a Hog Cholera Lethal Strain},
    journal = {Journal of Animal and Veterinary Advances},
    volume = {7},
    number = {1},
    pages = {94-99},
    year = {2008},
    issn = {1680-5593},
    doi = {javaa.2008.94.99},
    url = {https://makhillpublications.co/view-article.php?issn=1680-5593&doi=javaa.2008.94.99},
    author = {Maria Antonia Coba Ayala,E. Pablo Correa Giron,Atalo Martinez Lara,Susana Mendoza Elvira,Abel Ciprian Carrasco,Oscar Torre and},
    keywords = {Hog Cholera,classical swine fever,pav-250 vaccinial strain,ald pathogenic strain,immunization},
    abstract = {Pathogenic Hog Cholera (HC) Virus (V) generally kills inoculated pigs before the development of detectable antibodies, making difficult to produce an immune sera against the ALD exposition pathogenic live-virus. With this last purpose a procedure was evaluated by inoculating 2 HCV seronegative pigs, initially with highly diluted dosages of challenge HCV (ALD strain/with an initial titer of 10<SUP>4.99</SUP>CCID<SUB>50</SUB>/mL) and then progressively with more concentrated dosages (from 10<SUP>-11</SUP> to 10<SUP>-1</SUP>). This allowed to produce the disease with a long incubation period. The 2 pigs presented fever and HC clinical signs and survived 30 and 38 days after inoculation, respectively. In a second phase, in an attempt to produce a HC immune serum, 5 groups of 4 susceptible pigs were immunized as follows Group (G) I, Negative Control; G II vaccinated with the PAV-250 HC vaccine; G III, inoculated with 1 mL ALD-HCV (10<SUP>4.0</SUP>/mL); G IV, vaccinated and challenged with ALD-HCV; G V, vaccinated twice andALD-HCV challenged. G I was negative. HC-antibody titres of  >=1:10 were detected at 14 Post Challenge (PC) days in Control Groups II, IV and V and at 15 PC. days in Group III. HC antibodies developed in G III because pigs had enough time for antibody production after being inoculated. The utilized challenge dilution (10<SUP>4.0</SUP> /mL) was satisfactory for obtaining immune sera against the pathogenic live HCV-ALD, in G III; Control groups II, IV and V also produced satisfactory immune sera.}
    }